KX 02

Drug Profile

KX 02

Alternative Names: KX-2361; KX02

Latest Information Update: 21 Oct 2016

Price : $50

At a glance

  • Originator Kinex Pharmaceuticals
  • Developer Athenex; Roswell Park Cancer Institute; Xiangxue Pharmaceutical
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Src-Family kinase inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Glioma
  • Preclinical Brain cancer

Most Recent Events

  • 18 Oct 2016 Xiangxue Pharmaceuticals files an IND application with the China FDA in China for Cancer
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Brain-cancer in China (PO)
  • 24 Dec 2014 Phase-I clinical trials in Glioma (Metastatic disease) in USA (PO) (9173057; NCT02326441)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top